BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Keskin S, Yıldız I, Sen F, Aydogan F, Kilic L, Ekenel M, Saglam S, Sakar B, Disci R, Aykan F. Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC). Clin Transl Oncol 2013;15:403-8. [PMID: 23054756 DOI: 10.1007/s12094-012-0942-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhou C, Ma T, Shi M, Xi W, Wu J, Yang C, Zhu Z, Zhang J. Dose-finding study of modified FLOT (mFLOT) regimen as first-line treatment in Chinese patients with metastatic adenocarcinoma of stomach. Cancer Chemother Pharmacol 2020;85:113-9. [PMID: 31691079 DOI: 10.1007/s00280-019-03982-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
2 Erdem GU, Bozkaya Y, Ozdemir NY, Demirci NS, Yazici O, Zengin N. 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane. Bosn J Basic Med Sci 2018;18:170-7. [PMID: 28941466 DOI: 10.17305/bjbms.2017.2258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
3 Petrelli F, Tomasello G, Ghidini M, Passalacqua R, Barni S. Modified schedules of DCF chemotherapy for advanced gastric cancer: a systematic review of efficacy and toxicity. Anticancer Drugs. 2017;28:133-141. [PMID: 27749286 DOI: 10.1097/cad.0000000000000436] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bozkaya Y, Doğan M, Yazıcı O, Erdem GU, Demirci NS, Zengin N. The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma. Bosn J Basic Med Sci 2017;17:138-43. [PMID: 28273032 DOI: 10.17305/bjbms.2017.1684] [Reference Citation Analysis]
5 Maeda O, Matsuoka A, Miyahara R, Funasaka K, Hirooka Y, Fukaya M, Nagino M, Kodera Y, Goto H, Ando Y. Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study. World J Gastroenterol 2017; 23(6): 1090-1097 [PMID: 28246483 DOI: 10.3748/wjg.v23.i6.1090] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wang J, Xu R, Li J, Bai Y, Liu T, Jiao S, Dai G, Xu J, Liu Y, Fan N, Shu Y, Ba Y, Ma D, Qin S, Zheng L, Chen W, Shen L. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer 2016;19:234-44. [PMID: 25604851 DOI: 10.1007/s10120-015-0457-4] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 10.6] [Reference Citation Analysis]
7 Luo Y, Li Z, Cui S, Shen C, Zhao J, Wu M, Li Y, Wang M, Chen R, Liu Z. Joint detection of ERCC1, TUBB3, and TYMS guidance selection of docetaxel, 5-fluorouracil and cisplatin (DDP) individual chemotherapy in advanced gastric cancer patients. Eur J Med Res. 2014;19:50. [PMID: 25223338 DOI: 10.1186/s40001-014-0050-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
8 Chen L, Song MQ, Lin HZ, Hao LH, Jiang XJ, Li ZY, Chen YX. Chemotherapy and resection for gastric cancer with synchronous liver metastases. World J Gastroenterol 2013; 19(13): 2097-2103 [PMID: 23599631 DOI: 10.3748/wjg.v19.i13.2097] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]